26 documents

Read All
00:47 , Jul 27, 2018 |  BC Innovations  |  Product R&D

Syncona’s sister act

With the final pieces of its gene therapy portfolio in place, Syncona Investment Management Ltd. thinks its five “sister companies” are poised to capitalize on recent regulatory and technological advances in gene therapy, and push...
Read More
21:15 , May 18, 2018 |  BioCentury  |  Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
Read More
16:17 , Sep 8, 2017 |  BC Week In Review  |  Financial News

Nightstar, Deciphera, NuCana propose NASDAQ IPOs

Ophthalmic gene therapy company Nightstar Therapeutics Ltd. (London, U.K.) (formerly NightstaRx Ltd.) filed to raise up to $86.3 million on Aug. 31 in an IPO on NASDAQ underwritten by Jefferies, Leerink, BMO Capital Markets, Wedbush...
Read More
21:35 , Sep 1, 2017 |  BC Extra  |  Financial News

Nightstar, Deciphera, NuCana propose NASDAQ IPOs

Ophthalmic gene therapy company Nightstar Therapeutics Ltd. (London, U.K.) (formerly NightstaRx Ltd.) filed to raise up to $86.3 million on Thursday in an IPO on NASDAQ underwritten by Jefferies, Leerink, BMO Capital Markets, Wedbush and...
Read More
23:24 , Apr 6, 2017 |  BC Extra  |  Company News

Management tracks

Sanofi (Euronext:SAN; NYSE:SNY) said David Meeker will resign as EVP of its Sanofi Genzyme unit at the end of June. The company promoted Bill Sibold to the position, effective July 1. Sibold is head of...
Read More
20:53 , Mar 23, 2017 |  BC Week In Review  |  Clinical News

AAV-XLRPGR: Ph I/II started

NightstaRx began an open-label, dose-escalation Phase I/II trial to evaluate single subretinal injections of AAV-XLRPGR in about 24 male patients. NightstaRx Ltd. , London, U.K.  Product: AAV-XLRPGR   Business: Ophthalmic  Molecular target: NA  Description: Adeno-associated...
Read More
07:00 , Sep 13, 2016 |  BC Extra  |  Company News

Management tracks

Gene therapy company NightstaRx Ltd. (London, U.K.) named Gregory Robinson CSO. He was CSO at Agilis Biotherapeutics LLC (Cambridge, Mass.). Wound care company Acelity L.P. Inc. (San Antonio, Texas) said EVP and CFO Tom Casey...
Read More
07:00 , May 19, 2016 |  BC Innovations  |  Finance

Found in translation

Mark Zipkin, Staff Writer  With almost $1 billion in new venture funds in the last year and a half aimed at academic research, Europe is showing signs of a dedicated effort among investors and universities...
Read More
07:00 , May 16, 2016 |  BioCentury  |  Finance

Global ambitions

European biotechs not only missed out on the extended bull market that allowed U.S. biotechs to fill their coffers, but also on what could have been an arbitrage opportunity for U.S. investors who found domestic...
Read More
02:29 , Dec 11, 2015 |  BC Extra  |  Financial News

Freeline launches with L25 million from Syncona

Freeline Therapeutics (London, U.K.) is raising L25 million ($37.7 million) in a series A round from Syncona LLP. Freeline, which is developing gene therapies for bleeding and other disorders, spun out of University College London...
Read More